APA (7th ed.) Citation

Bazou, D., Majumder, M. M., Tierney, C., O'Rourke, S., Anttila, P., Silvennoinen, R. H., . . . O'Gorman, P. (2018). Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing Allows Identification of Physiologically Distinct Sub-Clones That Can Inform Therapeutic and Drug Development Strategies. Blood, 132(Supplement 1), 1901. https://doi.org/10.1182/blood-2018-99-115910

Chicago Style (17th ed.) Citation

Bazou, Despina, Muntasir M. Majumder, Ciara Tierney, Sinead O'Rourke, Pekka Anttila, Raija Helena Silvennoinen, Caroline A. Heckman, Paul Dowling, and Peter O'Gorman. "Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing Allows Identification of Physiologically Distinct Sub-Clones That Can Inform Therapeutic and Drug Development Strategies." Blood 132, no. Supplement 1 (2018): 1901. https://doi.org/10.1182/blood-2018-99-115910.

MLA (9th ed.) Citation

Bazou, Despina, et al. "Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing Allows Identification of Physiologically Distinct Sub-Clones That Can Inform Therapeutic and Drug Development Strategies." Blood, vol. 132, no. Supplement 1, 2018, p. 1901, https://doi.org/10.1182/blood-2018-99-115910.